Frequency of the Apolipoprotein E ε4 Allele in a Memory Clinic Cohort in Beijing: A Naturalistic Descriptive Study

Wang, Xiao; Wang, Huali; Li, Huiying; Li, Tao; Yu, Xin

doi:10.1371/journal.pone.0099130

Cited by 13 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected 28 studies described in 26 articles [11-13, 20, 24-45]. The study of Norberg et al [20] was divided into 3 parts (northern Europe, middle Europe, and southern Europe), so there are 2 more studies other than the number of articles.…”

Section: Resultsmentioning

confidence: 99%

“…Dik et al [10] reported that cognitively normal elderly people who carried APOE e4 alleles had greater rates of cognitive decline than non-carriers. Wang et al [11] reported that the APOE e4 allele prevalence was higher in the SCD group (14.7%) than that in the control group (7.3%). However, 2 case-control studies conducted by Verdile et al [12] and Caselli et al [13] showed that the prevalence of APOE e4 did not significantly differ between healthy controls and SCD groups.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

Background and Purpose: Subjective cognitive decline (SCD) is a condition associated with increased risk of Alzheimer’s disease. This study performs a meta-analysis to estimate the prevalence of the Apolipoprotein E e4 (APOE e4) allele in SCD and the association of APOE e4 with SCD. Methods: The MEDLINE, EMBASE, and Cochrane Library databases were searched. Meta-analyses were conducted using STATA 12.0 software. When significant heterogeneity was present (I² >50% and p < 0.05), we conducted stratified and meta-regression analyses to explore possible reasons for heterogeneity. Results: We selected a total of 28 studies that were conducted in Australia, the United States, northern Europe, middle Europe, southern Europe, and Asia. The sample size of the SCD group was 6,044. Thirteen studies included a healthy control group (total control cohort of 3,822), whereas the remaining 15 studies were single-arm studies of SCD groups. The APOE e4 allele was associated with SCD (OR 1.12 [1.00–1.25]; p = 0.04). The pooled estimate for APOE e4 carrier prevalence was 32% (95% CI 28–35). Due to the significant heterogeneity in prevalence estimates, we performed stratified and meta-regression analyses and found that age and northern European residency were significantly associated with heterogeneity. Conclusion: The results of this meta-analysis indicate a weak association between APOE e4 and SCD. Age and northern European residency are the critical factors that determine heterogeneity in the APOE e4-associated prevalence of SCD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…ApoE genotyping (ε2, ε3, and ε4 allele) was performed on DNA samples from the subjects’ blood, as previously described 101 .…”

Section: Methodsmentioning

confidence: 99%

A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients

Meng

Hua

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

Amnestic mild cognitive impairment (aMCI) is a sub-clinical condition characterized by memory deficits that are not severe enough to affect daily functioning. Here we investigated two potential biomarkers found in the cerebrospinal fluid of AD patients, APLP1-derived Aβ-like peptides 28 (APL1β28) and clusterin plasma levels, in terms of their relationship to cognitive function, as reflected in the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the Cognitive Assessment Screening Instrument (CASI) in aMCI patients. Forty-seven aMCI patients and thirty-five age- and gender-matched healthy adult controls were recruited for this study. Using the ELISA method, we found that the mean concentrations of both APL1β28 and clusterin were not significantly different between the control and aMCI groups. The APL1β28 levels were positively correlated with clusterin and that both were negatively correlated with the MMSE scores of the aMCI patients. Clusterin levels were negatively correlated with the MoCA and CASI scores of the aMCI patients. Using multivariate analysis, the correlation between clusterin and MMSE/MoCA/CASI was independent of other AD risk factors including age, education, sex, body mass index and ApoE genotype. The data presented here demonstrate that plasma clusterin levels reflect cognitive function in aMCI patients.

show abstract

“…From May to November 2018, 36 patients with MCI and 29 patients with AD were recruited from the case registry of the Dementia Care & Research Center of Peking University Institute of Mental Health. The case registry has been described in a previous study (33). Briefly, the participants completed a standardized neuropsychological assessment, underwent clinical interviews and brain imaging examinations, and received a clinical diagnosis by a memory specialist.…”

Section: Participantsmentioning

confidence: 99%

Decision-Making Under Ambiguity or Risk in Individuals With Alzheimer’s Disease and Mild Cognitive Impairment

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Making advantageous decisions is essential in everyday life. Our objective was to assess how patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) make decisions under conditions of ambiguity or risk. In addition, the study also aimed to examine the relationship between decision-making competence and memory and executive function.Methods: Patients with MCI (n = 36) and AD (n = 29) and healthy elderly controls (HC, n = 34) were recruited from the memory clinic. All subjects were administered a comprehensive neuropsychological battery test. We used the Iowa Gambling Task (IGT) to measure decisionmaking under ambiguity and the Game of Dice Task (GDT) to measure decision-making under risk. Pearson's correlation was used to examine the relationship between the performance of IGT and GDT with delayed recall and the Stroop test.Results: In the GDT, MCI and AD patients presented similar performance but showed different patterns when compared with the HC group. The proportion of those making advantageous choices was lower in the AD group than in the HC group (p = 0.01), while the MCI and HC groups did not differ (p = 0.14). Meanwhile, concerning the ratio of accepting negative feedback, the AD (p < 0.01) group was significantly different from the HC patients, but the MCI (p = 0.06) and HC groups did not differ. In the IGT, MCI and AD patients selected randomly from advantageous and disadvantageous decks (p = 0.94 and p = 0.54), showing no significant change in performance over time. In contrast, the HC group made increasingly frequent advantageous selections over time (p = 0.04). Furthermore, the proportion of advantageous decision-makers for the GDT had a linear relationship with delayed recall of the Hopkins Verbal Learning Test and Stroop color words (p < 0.01 and p < 0.01, respectively). Conclusion:Our findings suggest that decision-making ability under ambiguity is compromised in MCI and AD, and the decision-making under risk is only impaired in AD. Reduced decision-making performance under risk is closely correlated with lower executive functions and memory.

show abstract

Frequency of the Apolipoprotein E ε4 Allele in a Memory Clinic Cohort in Beijing: A Naturalistic Descriptive Study

Cited by 13 publications

References 47 publications

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients

Decision-Making Under Ambiguity or Risk in Individuals With Alzheimer’s Disease and Mild Cognitive Impairment

Contact Info

Product

Resources

About